Tecartus (brexucabtagene autoleucel) / Gilead, Fosun Kite - LARVOL DELTA

Immune system state shapes clinical response to CAR-T therapy in mantle cell lymphoma (AACR 2026) - "Single-cell RNA sequencing (scRNA-seq) was performed on 56 blood samples from 44 MCL patients treated with brexucabtagene autoleucel, including 24 long-term responders (pre-CAR-T samples), 17 relapsed patients (13 with paired pre-CAR-T and post-relapse samples), and 3 refractory patients (paired pre- and post-CAR-T samples)...ISS provides a clinically actionable framework for predicting CAR-T response in MCL by capturing systemic immune dynamics. ISS-guided risk stratification may inform CAR-T optimization and rational combination strategies in MCL."

CAR T-Cell Therapy • Clinical • IO biomarker • Hematological Malignancies • Lymphoma • Mantle Cell Lymphoma • Oncology • LAG3 • TIGIT

Brexu-cel + dasatinib: Safety and feasibility of dasatinib pulses after brexucabtagene autoleucel to modulate CAR T cell activity in relapsed/refractory B cell acute lymphoblastic leukemia (AACR 2026) - "Abstract is embargoed at this time."

CAR T-Cell Therapy • Clinical • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Hematological Malignancies • Leukemia • Oncology

Validation and Clinical Assessment of BCMA and CD19 CAR-T by DxFLEX 13-Color Flow Cytometer and Incorporating Immunoregulatory Markers (USCAP 2026) - "Design: Patients receiving Breyanzi, Tecartus, Miltenyi, and Yescarta, for R/R B-cell lymphomas such as diffuse large B-cell Lymphoma, follicular lymphoma, chronic lymphocytic leukemia (n=32), and patients receiving Carvykti for R/R multiple myeloma or plasma cell leukemia (n=25), and normal blood samples (n=22) were included. CAR-T flow cytometry-based assay provides a rapid, sensitive and reliable method for monitoring CAR-T patients, facilitating early detection of treatment failure and toxicity. Incorporating immunoregulatory markers could enhance a real-time immune monitoring approach and potentially provide a personalized strategy for managing CAR-T patients."

CAR T-Cell Therapy • Clinical • IO biomarker • B Cell Lymphoma • Chronic Lymphocytic Leukemia • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • Leukemia • Lymphoma • Multiple Myeloma • Non-Hodgkin’s Lymphoma • Plasma Cell Leukemia • CD4 • CD69 • CD8 • IL2RA • ISG20 • PD-1 • SELL

FIRST-LINE ANAKINRA FOR CYTOKINE RELEASE SYNDROME AFTER ANTI-CD19 CAR-T CELLS: A SINGLE-CENTER EXPERIENCE (EBMT 2026) - "CAR-T cell products included axicabtagene ciloleucel (48%, n=29), tisagenlecleucel (35%, n=21), brexucabtagene autoleucel (15%, n=9) and lisocabtagene autoleucel (2%, n=1)...Anakinra dose escalation was required in 20% (n=6) of patients for ICANS, and additional treatments included tocilizumab (77%, n=23) and dexamethasone (72%, n=22) in the same group... Our findings support the use of anakinra at CRS onset as a feasible first-line strategy to mitigate inflammatory toxicities associated with CAR-T therapy, particularly in patients receiving axicabtagene ciloleucel. Indeed, we did not observe Grade 3-4 CRS events, and severe ICANS was limited to Grade 3 with lower steroid needs. Patients who did not develop CRS were not exposed to unnecessary treatment, as may occur with prophylactic approaches."

CAR T-Cell Therapy • Clinical • Cytokine release syndrome • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Inflammation • Lymphoma • Mantle Cell Lymphoma • Non-Hodgkin’s Lymphoma

ANTIBIOTIC TIMING AND IMPACT ON SURVIVAL OUTCOMES IN ANTI-CD19 AND ANTI-BCMA CAR-T CELL THERAPY (EBMT 2026) - "Particularly, PIM (piperacillin-tazobactam, imipenem, meropenem) are implicated with poor outcomes...CD19 products included lisocabtagene maraleucel, tisagenlecleucel, brexucabtagene autoleucel, and axicabtagene ciloleucel. BCMA products included idecabtagene vicleucel and ciltacabtagene autoleucel...Post CAR-T antibiotics were largely fourth generation cephalosporins such as cefepime, with vancomycin... Exposure to antibiotics in 30 days pre-CAR-T is associated with worse OS, even when adjusted for age, prior lines of therapy, and infection rate. Post-CAR-T antibiotics did not have an effect on PFS, OS or progression at first PET-CT scan. Clinicians should be judicious with antibiotic exposure in the 30 days prior to CAR-T therapy."

CAR T-Cell Therapy • Acute Lymphocytic Leukemia • B Cell Lymphoma • Hematological Malignancies • Infectious Disease • Leukemia • Lymphoma • Multiple Myeloma • Non-Hodgkin’s Lymphoma

COMPARATIVE VALIDATION OF NEUTROPHIL-BASED MODELS (CAR-HEMATOTOX, ALL-HEMATOTOX, AND E-IPM) FOR PREDICTING EARLY T-ICAHT–DEFINED PLATELET RECOVERY AFTER CAR-T THERAPY (EBMT 2026) - " In this prospective cohort, 135 patients received CAR-T therapy between 2022 and 2025, including autologous CD19 CAR-T (brexucabtagene autoleucel or academic 4-1BB–based CAR-T) for B-ALL/B-cell non-Hodgkin lymphoma (n=73), CD7 CAR-T for T-ALL/T-cell NHL (n=28), and BCMA CAR-T for multiple myeloma (n=34)... CAR-HT, ALL-HT, and eIPM effectively identify patients at higher risk of post-infusion thrombocytopenia within 30 days after CAR-T therapy. In ALL with predominant bone marrow blast involvement, ALL-HT may provide superior predictive performance."

CAR T-Cell Therapy • B Cell Non-Hodgkin Lymphoma • Bone Marrow Transplantation • Hematological Malignancies • Lymphoma • Multiple Myeloma • Non-Hodgkin’s Lymphoma • T Acute Lymphoblastic Leukemia • Thrombocytopenia • CD7

REAL WORLD INCIDENCE AND CHARACTERISTICS OF IMMUNE EFFECTOR CELL–ASSOCIATED HEMOPHAGOCYTIC LYMPHOHISTICYTOSIS: A GOCART COALITION STUDY ON BEHALF OF THE EBMT ADWP, CTIWP AND TCWP (EBMT 2026) - "Secondary HLH frequency was higher in patients treated with tisagenlecleucel (40,7%), followed by axicabtagene ciloleucel (37%), brexucabtagene autoleucel (14.8%), and others (7.4%)...Eleven patients underwent a bone marrow aspirate, with evidence of hemophagocytosis in 45% of cases.Twenty patients (80%) received treatment, most commonly with a combination of steroids and anakinra... This registry study characterizes CAR-related sHLH. Secondary HLH incidence differed between patients B-ALL and B-Lymphoma patients. Our study showed a better sHLH prognosis than what previously reported."

Clinical • Real-world • Real-world evidence • B Cell Lymphoma • Hematological Malignancies • Hemophagocytic lymphohistiocytosis • Immunology • Lymphoma • Multiple Myeloma • Non-Hodgkin’s Lymphoma • Rare Diseases

EARLY STEROID PROPHYLAXIS AS A STRATEGY TO REDUCE CAR T-CELL TOXICITIES WITHOUT AFFECTING EFFICACY (EBMT 2026) - "Early use of anakinra for grade 1 ICANS was implemented as well, in order to further reduce the incidence of severe neurotoxicity. After a median of 15 months from diagnosis (range 4–143), all patients (N=23) underwent lymphodepleting therapy with fludarabine and cyclophosphamide, followed by autologous CD19-directed CAR T-cell infusion. In line with approved indications, 18 patients (78%) with relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL, n = 13), r/r primary mediastinal large B-cell lymphoma (PMBCL, n = 2) or r/r follicular lymphoma (FL, n = 3) received axicabtagene ciloleucel (Yescarta), whereas 5 patients (22%) with r/r mantle cell lymphoma (MCL, n = 4) and r/r B-cell acute lymphoblastic leukemia (B-ALL, n = 1) received brexucabtagene autoleucel (Tecartus)...For persistent fever >72 hours or grade 2 CRS, all patients received a maximum of two 8-mg/kg IV doses of tocilizumab... Prophylactic dexamethasone before CAR T-cell infusion appears to be..."

CAR T-Cell Therapy • Clinical • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • Large B Cell Lymphoma • Leukemia • Lymphoma • Mantle Cell Lymphoma • Non-Hodgkin’s Lymphoma • Primary Mediastinal Large B-Cell Lymphoma

EXTRACELLULAR VESICLES AS NONINVASIVE BIOMARKERS OF IMMUNE AND ENDOTHELIAL ACTIVATION IN CAR T-CELL THERAPY RECIPIENTS (EBMT 2026) - " Thirty patients treated with commercial CAR T-cell products [axicabtagene ciloleucel (n=21), tisagenlecleucel (n=6), or brexucabtagene autoleucel (n=3)] were enrolled. EV profiling identified distinct immunologic and vascular signatures associated with CRS and NT, supporting their utility as real-time indicators of CAR T-mediated inflammation. This prospective analysis demonstrates that CD146⁺ EVs, particularly those derived from LK and EC compartments, are powerful, noninvasive biomarkers capable of anticipating CAR T-related toxicities before clinical onset. Elevated pre-Lym CD146⁺ LK EVs strongly predicted CRS, whereas rising CD146⁺ EC EVs distinguished patients progressing toward NT."

Biomarker • CAR T-Cell Therapy • Non-invasive • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • High-grade B-cell lymphoma • Lymphoma • Mantle Cell Lymphoma • Non-Hodgkin’s Lymphoma • CD31 • MCAM • PECAM1 • PTPRC

COMPARATIVE OUTCOMES OF LISOCABTAGENE MARALEUCEL (LISO-CEL) VERSUS AN EXTERNAL CONTROL ARM (ECA) IN PATIENTS WITH THIRD-LINE OR LATER (3L+) RELAPSED/REFRACTORY (R/R) MANTLE CELL LYMPHOMA (MCL) (EBMT 2026) - P1 | "Balancing was performed using trimmed, stabilized inverse probability of treatment weighting (IPTW).The primary analysis utilized the liso-cel–treated efficacy analysis cohort (LTEAC [n=75]; patients with PET-positive disease who failed ≥2 prior lines of systemic therapy, including a BTKi, alkylating agent, and rituximab [or other CD20-targeted agent] and received liso-cel at a target dose of 100×106 CAR+ T cells)...SOC regimens used in the 3L+ R/R MCL setting included chemoimmunotherapy (22.1%), covalent BTKi (19.7%), lenalidomide-based regimens (17.7%), bortezomib-based regimens (10.9%), CD19 CAR T cell therapy (brexucabtagene autoleucel; 10.1%), venetoclax-based regimens (6.3%), noncovalent BTKi (4.2%), chemotherapy (3.9%), and HSCT (2.6%).After IPTW adjustment, liso-cel treatment was associated with statistically significant improved outcomes versus SOC for the primary (ORR) and secondary endpoints (CR rate, PFS, and OS; Table)... Liso-cel demonstrated..."

Clinical • Bone Marrow Transplantation • Hematological Malignancies • Lymphoma • Mantle Cell Lymphoma

SUCCESSFUL IMPLEMENTATION OF CAR-T CELL THERAPY AT THE ONCOLOGY INSTITUTE IN WARSAW (EBMT 2026) - "Cyclophosphamide and fludarabine were administered on days 5-3, followed by the CAR-T cell drug infusion Yescarta (DLBCL) or Tecartus (MCL), depending on the diagnosis...All MCL patients were treated with the R-CHOP/RDHAP regimen with autotransplantation consolidation, followed by ibrutinib (n=3) or acalabrutinib (n=2) in subsequent lines...Ten patients received bridging therapy before CAR-T therapy, Pola-BR or R-GEMOX chemotherapy for DLBCL, and R-bendamustine for MCL...Three patients required tocilizumab...Two patients received four doses of Anakinra... CAR-T therapy appears to be a safe and tolerable procedure despite the occurrence of profound neutropenia and the development of CRS and ICAN syndromes. Severe CRS and ICANS occurred in less than 15% of patients."

CAR T-Cell Therapy • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Disorders • Hematological Malignancies • Infectious Disease • Lymphoma • Mantle Cell Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Thrombocytopenia

EARLY STEROID PROPHYLAXIS AS A STRATEGY TO REDUCE CAR T-CELL TOXICITIES WITHOUT AFFECTING EFFICACY (EBMT 2026) - "Early use of anakinra for grade 1 ICANS was implemented as well, in order to further reduce the incidence of severe neurotoxicity. After a median of 15 months from diagnosis (range 4–143), all patients (N=23) underwent lymphodepleting therapy with fludarabine and cyclophosphamide, followed by autologous CD19-directed CAR T-cell infusion. In line with approved indications, 18 patients (78%) with relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL, n = 13), r/r primary mediastinal large B-cell lymphoma (PMBCL, n = 2) or r/r follicular lymphoma (FL, n = 3) received axicabtagene ciloleucel (Yescarta), whereas 5 patients (22%) with r/r mantle cell lymphoma (MCL, n = 4) and r/r B-cell acute lymphoblastic leukemia (B-ALL, n = 1) received brexucabtagene autoleucel (Tecartus)...For persistent fever >72 hours or grade 2 CRS, all patients received a maximum of two 8-mg/kg IV doses of tocilizumab... Prophylactic dexamethasone before CAR T-cell infusion appears to be..."

CAR T-Cell Therapy • Clinical • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • Large B Cell Lymphoma • Leukemia • Lymphoma • Mantle Cell Lymphoma • Non-Hodgkin’s Lymphoma • Primary Mediastinal Large B-Cell Lymphoma

REAL WORLD INCIDENCE AND CHARACTERISTICS OF IMMUNE EFFECTOR CELL–ASSOCIATED HEMOPHAGOCYTIC LYMPHOHISTICYTOSIS: A GOCART COALITION STUDY ON BEHALF OF THE EBMT ADWP, CTIWP AND TCWP (EBMT 2026) - "Secondary HLH frequency was higher in patients treated with tisagenlecleucel (40,7%), followed by axicabtagene ciloleucel (37%), brexucabtagene autoleucel (14.8%), and others (7.4%)...Eleven patients underwent a bone marrow aspirate, with evidence of hemophagocytosis in 45% of cases.Twenty patients (80%) received treatment, most commonly with a combination of steroids and anakinra... This registry study characterizes CAR-related sHLH. Secondary HLH incidence differed between patients B-ALL and B-Lymphoma patients. Our study showed a better sHLH prognosis than what previously reported."

Clinical • Real-world • Real-world evidence • B Cell Lymphoma • Hematological Malignancies • Hemophagocytic lymphohistiocytosis • Immunology • Lymphoma • Multiple Myeloma • Non-Hodgkin’s Lymphoma • Rare Diseases

ANTIBIOTIC TIMING AND IMPACT ON SURVIVAL OUTCOMES IN ANTI-CD19 AND ANTI-BCMA CAR-T CELL THERAPY (EBMT 2026) - "Particularly, PIM (piperacillin-tazobactam, imipenem, meropenem) are implicated with poor outcomes...CD19 products included lisocabtagene maraleucel, tisagenlecleucel, brexucabtagene autoleucel, and axicabtagene ciloleucel. BCMA products included idecabtagene vicleucel and ciltacabtagene autoleucel...Post CAR-T antibiotics were largely fourth generation cephalosporins such as cefepime, with vancomycin... Exposure to antibiotics in 30 days pre-CAR-T is associated with worse OS, even when adjusted for age, prior lines of therapy, and infection rate. Post-CAR-T antibiotics did not have an effect on PFS, OS or progression at first PET-CT scan. Clinicians should be judicious with antibiotic exposure in the 30 days prior to CAR-T therapy."

CAR T-Cell Therapy • Acute Lymphocytic Leukemia • B Cell Lymphoma • Hematological Malignancies • Infectious Disease • Leukemia • Lymphoma • Multiple Myeloma • Non-Hodgkin’s Lymphoma

COMPARATIVE VALIDATION OF NEUTROPHIL-BASED MODELS (CAR-HEMATOTOX, ALL-HEMATOTOX, AND E-IPM) FOR PREDICTING EARLY T-ICAHT–DEFINED PLATELET RECOVERY AFTER CAR-T THERAPY (EBMT 2026) - " In this prospective cohort, 135 patients received CAR-T therapy between 2022 and 2025, including autologous CD19 CAR-T (brexucabtagene autoleucel or academic 4-1BB–based CAR-T) for B-ALL/B-cell non-Hodgkin lymphoma (n=73), CD7 CAR-T for T-ALL/T-cell NHL (n=28), and BCMA CAR-T for multiple myeloma (n=34)... CAR-HT, ALL-HT, and eIPM effectively identify patients at higher risk of post-infusion thrombocytopenia within 30 days after CAR-T therapy. In ALL with predominant bone marrow blast involvement, ALL-HT may provide superior predictive performance."

CAR T-Cell Therapy • B Cell Non-Hodgkin Lymphoma • Bone Marrow Transplantation • Hematological Malignancies • Lymphoma • Multiple Myeloma • Non-Hodgkin’s Lymphoma • T Acute Lymphoblastic Leukemia • Thrombocytopenia • CD7

FIRST-LINE ANAKINRA FOR CYTOKINE RELEASE SYNDROME AFTER ANTI-CD19 CAR-T CELLS: A SINGLE-CENTER EXPERIENCE (EBMT 2026) - "CAR-T cell products included axicabtagene ciloleucel (48%, n=29), tisagenlecleucel (35%, n=21), brexucabtagene autoleucel (15%, n=9) and lisocabtagene autoleucel (2%, n=1)...Anakinra dose escalation was required in 20% (n=6) of patients for ICANS, and additional treatments included tocilizumab (77%, n=23) and dexamethasone (72%, n=22) in the same group... Our findings support the use of anakinra at CRS onset as a feasible first-line strategy to mitigate inflammatory toxicities associated with CAR-T therapy, particularly in patients receiving axicabtagene ciloleucel. Indeed, we did not observe Grade 3-4 CRS events, and severe ICANS was limited to Grade 3 with lower steroid needs. Patients who did not develop CRS were not exposed to unnecessary treatment, as may occur with prophylactic approaches."

CAR T-Cell Therapy • Clinical • Cytokine release syndrome • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Inflammation • Lymphoma • Mantle Cell Lymphoma • Non-Hodgkin’s Lymphoma

THIOTEPA, CYCLOPHOSPHAMIDE AND FLUDARABINE CONDITIONING REGIMEN FOR ADULT PATIENTS WITH NON-HODGKIN LYMPHOMA UNDERGOING ALLOGENEIC STEM CELL TRANSPLANTATION: IMPACT OF DONOR MISMATCH ON OUTCOME (EBMT 2026) - "Median number of lines before transplant were 3 (range 1-10); 8 (23%) pts received autologous stem cell transplant, 6 (18%) pts CAR-T (3 tisagenlecleucel, 1 brexucabtagene autoleucel, 1 axicabtagene ciloleucel) and 6 (18%) bispecific antibodies (4 glofitamab, 2 mosunetuzumab). Our data highlight the efficacy of TCF conditioning for disease control in heavily pretreated lymphomas, with 1-year PFS and OS of 66% and 71% respectively. HSCT from mismatched donors had higher complications rate (mainly GVHD, despite the prevalent use of PT-Cy GVHD prophylaxis platform) and a tendency of lower 1-year OS."

Clinical • Bone Marrow Transplantation • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Graft versus Host Disease • Hematological Malignancies • Immunology • Infectious Disease • Lymphoma • Mantle Cell Lymphoma • Non-Hodgkin’s Lymphoma • Richter's Syndrome • T Cell Non-Hodgkin Lymphoma • Transplantation

EXTRACELLULAR VESICLES AS NONINVASIVE BIOMARKERS OF IMMUNE AND ENDOTHELIAL ACTIVATION IN CAR T-CELL THERAPY RECIPIENTS (EBMT 2026) - " Thirty patients treated with commercial CAR T-cell products [axicabtagene ciloleucel (n=21), tisagenlecleucel (n=6), or brexucabtagene autoleucel (n=3)] were enrolled. EV profiling identified distinct immunologic and vascular signatures associated with CRS and NT, supporting their utility as real-time indicators of CAR T-mediated inflammation. This prospective analysis demonstrates that CD146⁺ EVs, particularly those derived from LK and EC compartments, are powerful, noninvasive biomarkers capable of anticipating CAR T-related toxicities before clinical onset. Elevated pre-Lym CD146⁺ LK EVs strongly predicted CRS, whereas rising CD146⁺ EC EVs distinguished patients progressing toward NT."

Biomarker • CAR T-Cell Therapy • Non-invasive • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • High-grade B-cell lymphoma • Lymphoma • Mantle Cell Lymphoma • Non-Hodgkin’s Lymphoma • CD31 • MCAM • PECAM1 • PTPRC

FLU-CART: Fludarabine exposure in patients undergoing Fludarabine based lymphodepletion prior to CAR-T cell therapy (clinicaltrialsregister.eu) - P4 | N=75 | Not yet recruiting | Sponsor: Universitair Ziekenhuis Gent

New P4 trial • Hematological Malignancies • Oncology

NOVEL THERAPIES FOR RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA POST BRUTON'S TYROSINE KINASE INHIBITOR: A TARGETED LITERATURE REVIEW (ISPOR 2026) - "Five ongoing studies without outcomes reported are evaluating ixazomib, odronextamab, and rocbrutinib...Drugs evaluated included antibody-drug conjugates (ADCs) (zilovertamab, polatuzumab + obinutuzumab), bispecific antibodies (BsAbs) (mosunetuzumab-based, glofitamab), noncovalent BTKi (ncBTKi) (pirtobrutinib), chimeric antigen receptor T-cell (CAR-T) (brexucabtagene, lisocabtagene, tisagenlecleucel), ViPOR regimen (venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide), proteasome inhibitor (PI) (carfilzomib)... Preliminary data indicate promising but heterogenous results within drug classes. Interpretation is limited by small sample sizes and differences in study design, underscoring the need for further investigation in this area of high unmet need."

Review • Hematological Malignancies • Lymphoma • Mantle Cell Lymphoma

ZUMA-8: A Phase 1 Study of Brexucabtagene Autoleucel in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia. (PubMed, Blood) - P1 | "Patients with ≥2 prior lines of therapy (including a BTK inhibitor) underwent leukapheresis, followed by optional bridging therapy, then conditioning chemotherapy (fludarabine/cyclophosphamide) before infusing 1×106 (Cohort 1) or 2×106 (Cohort 2) anti-CD19 CAR T cells/kg. Patients in Cohort 3 (low tumor burden), and Cohort 4A (ibrutinib pre-treated closely to the apheresis) received 1×106 cells/kg...CAR T-cell expansion occurred in 4 patients (27%), with an apparent weak inverse correlation with absolute lymphocyte count (ALC) prior to the apheresis. Brexu-cel did not have any new safety signals in R/R CLL, and CAR T-cell expansion and responses occurred in patients with low tumor burden."

Journal • P1 data • Chronic Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Oncology

Brexucabtagene autoleucel (Brexucel) as a consolidation therapy in B-cell acute lymphoblastic leukemia (B-ALL) post HCVAD/minihcvd-inotuzumab-blinatumomab regimens: Initial Results of a prospective Phase 2 trial. (ASH 2025) - P1/2 | "Leukapheresis could be followed by further chemo-immunotherapy and then standard lymphodepletion (LD) with fludarabine-cyclophosphamide beforebrexucel infusion...Adverse events included cytokine release syndrome (CRS) in 8 (57%) pts (all grade 1); 3 pts neededsingle dose tocilizumab... From Dec 2024-July 31 2025, 28 pts have had leukapheresis,18 pts were infused and 14 pts with afollow-up (FU) >1 month post brexucel infusion were included in this report. The median age of theinfused pts was 35 years (range 19-77), and 5 pts (36%) were ³60 years of age. Ten pts (71%) receivedbrexcuel as FL consolidation therapy for adverse genomics, 3 FL pts (21%) had persistent (n=2)/recurrent(n=1) MRD, and 1 (7%) pt had R/R ALL."

Clinical • IO biomarker • P2 data • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Hematological Malignancies • Inflammation • Leukemia • KMT2A • TP53

Outcome of Patients with Mantle Cell Lymphoma after Failure of Anti-CD19 CAR-T Cell Therapy: A Descar-T Study By Lysa Group. (PubMed, Blood Adv) - "Brexucabtagene autoleucel (brexu-cel) is the anti-CD19 CAR-T therapy approved for the treatment of relapse/refractory (RR) mantle cell lymphoma (MCL)...Forty-nine patients received salvage therapy: 16 lenalidomide ± rituximab (Len/R2), 13 immunochemotherapy (ICT), 8 Bruton tyrosine kinase inhibitor ± venetoclax (BTKi/Ven), 7 a bispecific T-cell engager (TCE), 3 another targeted therapy, and 2 radiations...Notably, none of the TCE responders have relapsed to date (DOR of 100%). Our series highlights the poor outcomes of MCL patients following CAR-T failure and suggest a potential benefit of bispecific antibodies in this population."

IO biomarker • Journal • Hematological Malignancies • Lymphoma • Mantle Cell Lymphoma • Oncology • TP53

Ibrutinib exposure correlates with improved efficacy of CAR T cells in patients with mantle cell lymphoma. (PubMed, Blood Adv) - P2 | "The pivotal ZUMA-2 trial evaluated the chimeric antigen receptor (CAR) T-cell therapy brexucabtagene autoleucel (brexu-cel) for the treatment of relapsed/refractory (R/R) mantle cell lymphoma (MCL), and ultimately led to the approval of brexu-cel for R/R MCL. Here we report a retrospective analysis of data and samples from ZUMA-2, analyzed by exposure to class of Bruton tyrosine kinase inhibitor (BTKi; first-generation ibrutinib vs second-generation acalabrutinib) in a treatment line before brexu-cel...Our findings revealed CAR T-cell phenotypic associations with previous BTKi use, and highlight BTKi exposure as a potentially important clinical variable in ZUMA-2 worthy of further study in efforts to improve CAR T-cell therapies. This trial was registered at www.ClinicalTrials.gov as NCT02601313."

Journal • Retrospective data • Hematological Malignancies • Lymphoma • Mantle Cell Lymphoma • Oncology

Rapidly Evolving AKI after CAR-T therapy: A Case for Clinical Vigilance and Timely Renal Support (NKF-SCM 2026) - "METHODS/CASE SUMMARY A 34-year-old male diagnosed with B-cell acute lymphoblastic leukemia (B-ALL) with relapse was admitted for CAR-T therapy with brexucabtagene autoleucel...Four doses of tocilizumab and dexamethasone were given for neurotoxicity...Rasburicase and allopurinol were given due to concern for TLS...Clinicians must maintain high clinical vigilance with close and proactive monitoring of AKI and prompt response. Early initiation of renal replacement therapy in this clinical setting may provide both organ support and mitigate inflammation-related injury."

Clinical • Acute Kidney Injury • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • CNS Disorders • Hematological Malignancies • Hypotension • Leukemia • Nephrology • Renal Disease